

Luigi Messori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6936670/publications.pdf>

Version: 2024-02-01

341
papers

16,280
citations

14655

66
h-index

29157

104
g-index

353
all docs

353
docs citations

353
times ranked

11855
citing authors

#	ARTICLE	IF	CITATIONS
1	Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs. <i>Coordination Chemistry Reviews</i> , 2009, 253, 1692-1707.	18.8	513
2	Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. <i>Medicinal Research Reviews</i> , 2010, 30, 550-580.	10.5	431
3	Gold(III) Complexes as Potential Antitumor Agents: Solution Chemistry and Cytotoxic Properties of Some Selected Gold(III) Compounds. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 3541-3548.	6.4	325
4	Clioquinol, a Drug for Alzheimer's Disease Specifically Interfering with Brain Metal Metabolism:Â Structural Characterization of Its Zinc(II) and Copper(II) Complexes. <i>Inorganic Chemistry</i> , 2004, 43, 3795-3797.	4.0	275
5	Gold(III) Complexes with Bipyridyl Ligands:Â Solution Chemistry, Cytotoxicity, and DNA Binding Properties. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 1672-1677.	6.4	267
6	Emerging Protein Targets for Anticancer Metallodrugs: Inhibition of Thioredoxin Reductase and Cathepsin B by Antitumor Ruthenium(II)â~Arene Compounds. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 6773-6781.	6.4	258
7	Gold(III) compounds as anticancer agents: Relevance of goldâ€protein interactions for their mechanism of action. <i>Journal of Inorganic Biochemistry</i> , 2008, 102, 564-575.	3.5	249
8	NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry. <i>Molecules</i> , 2019, 24, 1995.	3.8	249
9	Gold complexes inhibit mitochondrial thioredoxin reductase: consequences on mitochondrial functions. <i>Journal of Inorganic Biochemistry</i> , 2004, 98, 1634-1641.	3.5	196
10	Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives. <i>Drug Discovery Today</i> , 2010, 15, 1070-1078.	6.4	193
11	Structural and Solution Chemistry, Antiproliferative Effects, and DNA and Protein Binding Properties of a Series of Dinuclear Gold(III) Compounds with Bipyridyl Ligands. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 5524-5531.	6.4	189
12	The binding properties of two antitumor ruthenium(III) complexes to apotransferrin.. <i>Journal of Biological Chemistry</i> , 1994, 269, 2581-2588.	3.4	183
13	Molecular Mechanisms and Proposed Targets for Selected Anticancer Gold Compounds. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 2647-2660.	2.1	176
14	New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects <i>in vitro</i>: Mechanistic and pharmacological implications. <i>FEBS Letters</i> , 2008, 582, 844-847.	2.8	152
15	A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from <i>Leishmania infantum</i> in complex with auranofin reveals a dual mechanism of enzyme inhibition. <i>Amino Acids</i> , 2012, 42, 803-811.	2.7	148
16	Aluminum, copper, iron and zinc differentially alter amyloid-AÎ²1â€42 aggregation and toxicity. <i>International Journal of Biochemistry and Cell Biology</i> , 2011, 43, 877-885.	2.8	147
17	The binding properties of two antitumor ruthenium(III) complexes to apotransferrin. <i>Journal of Biological Chemistry</i> , 1994, 269, 2581-8.	3.4	141
18	Challenges Associated with Metal Chelation Therapy in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 457-468.	2.6	139

#	ARTICLE	IF	CITATIONS
19	ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme. <i>Chemical Communications</i> , 2007, , 156-158.	4.1	137
20	Metal Ion Physiopathology in Neurodegenerative Disorders. <i>NeuroMolecular Medicine</i> , 2009, 11, 223-238.	3.4	131
21	A spectroscopic study of the reaction of NAMI, a novel ruthenium(III) anti-neoplastic complex, with bovine serum albumin. <i>FEBS Journal</i> , 2000, 267, 1206-1213.	0.2	129
22	Gold(III) compounds as anticancer drugs. <i>Gold Bulletin</i> , 2007, 40, 73-81.	2.7	128
23	Cisplatin binding to proteins: A structural perspective. <i>Coordination Chemistry Reviews</i> , 2016, 315, 67-89.	18.8	126
24	Mechanisms of Cytotoxicity of Selected Organogold(III) Compounds. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 6761-6765.	6.4	125
25	Formation of Supramolecular Structures between DNA and Starburst Dendrimers Studied by EPR, CD, UV, and Melting Profiles. <i>Macromolecules</i> , 2000, 33, 7842-7851.	4.8	123
26	A comparative study of aluminum(III), gallium(III), indium(III), and thallium(III) binding to human serum transferrin. <i>Coordination Chemistry Reviews</i> , 2002, 228, 237-262.	18.8	123
27	Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study. <i>Journal of Biological Inorganic Chemistry</i> , 2009, 14, 1139-1149.	2.6	119
28	DNA as a Possible Target for Antitumor Ruthenium(III) Complexes. <i>Archives of Biochemistry and Biophysics</i> , 2000, 376, 156-162.	3.0	115
29	Clioquinol Decreases Amyloid- β Burden and Reduces Working Memory Impairment in a Transgenic Mouse Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 423-440.	2.6	115
30	Cisplatin binding to human serum albumin: a structural study. <i>Chemical Communications</i> , 2015, 51, 9436-9439.	4.1	115
31	Use of Hydrophobic Ligands for the Stabilization of Low-Valent Transition Metal Complexes. 1. The Effect of N-Methylation of Linear Tetraazaalkane Ligands on the Properties of Their Copper Complexes. <i>Journal of the American Chemical Society</i> , 1995, 117, 8353-8361.	13.7	108
32	Structural Investigation of Cisplatin-Protein Interactions: Selective Platination of His19 in a Cuprozinc Superoxide Dismutase. <i>Angewandte Chemie - International Edition</i> , 2006, 45, 1267-1269.	13.8	107
33	Acid-sensitive polyethylene glycol conjugates of doxorubicin: preparation, in vitro efficacy and intracellular distribution. <i>Bioorganic and Medicinal Chemistry</i> , 1999, 7, 2517-2524.	3.0	106
34	Structural Characterization, Solution Studies, and DFT Calculations on a Series of Binuclear Gold(III) Oxo Complexes: Relationships to Biological Properties. <i>Inorganic Chemistry</i> , 2008, 47, 2368-2379.	4.0	102
35	Interactions of Selected Gold(III) Complexes with Calf Thymus DNA. <i>Biochemical and Biophysical Research Communications</i> , 2001, 281, 352-360.	2.1	98
36	Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound. <i>Journal of Biological Inorganic Chemistry</i> , 2009, 14, 761-770.	2.6	98

#	ARTICLE	IF	CITATIONS
37	Identification of the iron ions of high potential iron protein from <i>Chromatium vinosum</i> within the protein frame through two-dimensional NMR experiments. <i>Journal of the American Chemical Society</i> , 1992, 114, 3332-3340.	13.7	97
38	Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin. <i>Investigational New Drugs</i> , 2003, 21, 401-411.	2.6	95
39	Thioredoxin reductase, an emerging target for anticancer metallodrugs. Enzyme inhibition by cytotoxic gold(III) compounds studied with combined mass spectrometry and biochemical assays. <i>MedChemComm</i> , 2011, 2, 50-54.	3.4	94
40	Determinants for Tight and Selective Binding of a Medicinal Dicarbene Gold(I) Complex to a Telomeric DNA G-C Quadruplex: a Joint ESI MS and XRD Investigation. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 4256-4259.	13.8	93
41	Exploring Metallodrug-Protein Interactions by ESI Mass Spectrometry: The Reaction of Anticancer Platinum Drugs with Horse Heart Cytochrome c. <i>ChemMedChem</i> , 2006, 1, 413-417.	3.2	91
42	Auranofin, Et ₃ PAuCl, and Et ₃ PAuI Are Highly Cytotoxic on Colorectal Cancer Cells: A Chemical and Biological Study. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 997-1001.	2.8	91
43	Investigation of Cu ₂ Co ₂ SOD and its anion derivatives. Proton NMR and electronic spectra. <i>Journal of the American Chemical Society</i> , 1985, 107, 4391-4396.	13.7	89
44	Reactions of gold(III) complexes with serum albumin. <i>FEBS Journal</i> , 2003, 270, 4655-4661.	0.2	89
45	Mass spectrometric analysis of ubiquitin-platinum interactions of leading anticancer drugs: MALDI versus ESI. <i>Journal of Analytical Atomic Spectrometry</i> , 2007, 22, 960-967.	3.0	89
46	Insights on the mechanism of thioredoxin reductase inhibition by Gold N-heterocyclic carbene compounds using the synthetic linear Selenocysteine containing C-terminal peptide hTrxR(488-499): An ESI-MS investigation. <i>Journal of Inorganic Biochemistry</i> , 2014, 136, 161-169.	3.5	88
47	ESI-MS Characterisation of Protein Adducts of Anticancer Ruthenium(II)-Arene PTA (RAPTA) Complexes. <i>ChemMedChem</i> , 2007, 2, 631-635.	3.2	86
48	Chelation therapy for neurodegenerative diseases. <i>Medicinal Research Reviews</i> , 2009, 29, 547-570.	10.5	82
49	Crystal structure and solution chemistry of the cytotoxic complex 1,2-dichloro(o-phenanthroline)gold(III) chloride. <i>Inorganica Chimica Acta</i> , 2000, 311, 1-5.	2.4	81
50	Trace Copper(II) or Zinc(II) Ions Drastically Modify the Aggregation Behavior of Amyloid- β 42: An AFM Study. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 1323-1329.	2.6	81
51	Coordination modes of histidine. 10. Iron(III) tyrosinate models. Synthesis and spectroscopic and stereochemical studies of iron(III) complexes of N-salicylidene-L-amino acids. <i>Inorganic Chemistry</i> , 1987, 26, 1031-1038.	4.0	79
52	A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl ₄ (Ind) ₂] and serum proteins. <i>Journal of Inorganic Biochemistry</i> , 2004, 98, 1135-1142.	3.5	79
53	Potential pathogenic role of β 2-amyloid β 42-aluminum complex in Alzheimer's disease. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 731-746.	2.8	79
54	Rationalization of the inhibition activity of structurally related organometallic compounds against the drug target cathepsin B by DFT. <i>Dalton Transactions</i> , 2010, 39, 5556.	3.3	79

#	ARTICLE	IF	CITATIONS
55	[Au ₂ (phen ² Me) ₂ (μ_4 -O) ₂](PF ₆) ₂ , a Novel Dinuclear Gold(III) Complex Showing Excellent Antiproliferative Properties. ACS Medicinal Chemistry Letters, 2010, 1, 336-339.	2.8	79
56	Chemistry and Biology of Two Novel Gold(I) Carbene Complexes as Prospective Anticancer Agents. Inorganic Chemistry, 2014, 53, 2396-2403.	4.0	79
57	Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers. British Journal of Cancer, 2003, 88, 1484-1491.	6.4	78
58	Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: New insights from X-ray diffraction and mass spectrometry studies. Journal of Inorganic Biochemistry, 2008, 102, 995-1006.	3.5	77
59	Solution chemistry and cytotoxic properties of novel organogold(III) compounds. Bioorganic and Medicinal Chemistry, 2004, 12, 6039-6043.	3.0	76
60	μ -[Ru(CO) ₃] ²⁺ Selectively Targets the Histidine Residues of the β 2-Amyloid Peptide 1-28. Implications for New Alzheimer's Disease Treatments Based on Ruthenium Complexes. Inorganic Chemistry, 2010, 49, 4720-4722.	4.0	76
61	The mode of action of anticancer gold-based drugs: a structural perspective. Chemical Communications, 2013, 49, 10100.	4.1	76
62	Copper and zinc dimetabolism in the mouse brain upon chronic cuprizone treatment. Cellular and Molecular Life Sciences, 2005, 62, 1502-1513.	5.4	74
63	Synthesis, Structural Characterization, Solution Behavior, and in Vitro Antiproliferative Properties of a Series of Gold Complexes with 2-(2-Pyridyl)benzimidazole as Ligand: Comparisons of Gold(III) versus Gold(I) and Mononuclear versus Binuclear Derivatives. Inorganic Chemistry, 2012, 51, 3161-3171.	4.0	74
64	A BINOL-based chiral polyammonium receptor for highly enantioselective recognition and fluorescence sensing of (S,S)-tartaric acid in aqueous solution. Chemical Communications, 2012, 48, 10428.	4.1	73
65	Iridium(I) Compounds as Prospective Anticancer Agents: Solution Chemistry, Antiproliferative Profiles and Protein Interactions for a Series of Iridium(I) π -Heterocyclic Carbene Complexes. Chemistry - A European Journal, 2016, 22, 12487-12494.	3.3	71
66	Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections. BioMetals, 2014, 27, 787-791.	4.1	70
67	Protein Metalation by Anticancer Metallodrugs: A Joint ESI MS and XRD Investigative Strategy. Chemistry - A European Journal, 2017, 23, 6942-6947.	3.3	69
68	Decomposition of Ascorbic Acid in the Presence of Cadmium Ions Leads to Formation of a Polymeric Cadmium Oxalate Species with Peculiar Structural Features. Inorganic Chemistry, 2002, 41, 4312-4314.	4.0	67
69	The reaction of artemisinins with hemoglobin: A unified picture. Bioorganic and Medicinal Chemistry, 2006, 14, 2972-2977.	3.0	66
70	Metal compounds as inhibitors of β 2-amyloid aggregation. Perspectives for an innovative metallothrapeutics on Alzheimer's disease. Coordination Chemistry Reviews, 2012, 256, 2357-2366.	18.8	65
71	Gold(III) compounds as potential antitumor agents: Cytotoxicity and DNA binding properties of some selected polyamine-gold(III) complexes. Inorganica Chimica Acta, 1998, 281, 90-94.	2.4	64
72	The crystal structure of the complex between a disaccharide anthracycline and the DNA hexamer d(CGATCG) reveals two different binding sites involving two DNA duplexes. Nucleic Acids Research, 2003, 31, 1464-1469.	14.5	64

#	ARTICLE	IF	CITATIONS
73	Antimalarial properties of green tea. <i>Biochemical and Biophysical Research Communications</i> , 2007, 353, 177-181.	2.1	64
74	Reactions of medicinally relevant gold compounds with the C-terminal motif of thioredoxin reductase elucidated by MS analysis. <i>Chemical Communications</i> , 2010, 46, 7001.	4.1	64
75	Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 656-660.	2.8	64
76	Cisplatin Binding to Proteins: Molecular Structure of the Ribonuclease A Adduct. <i>Inorganic Chemistry</i> , 2014, 53, 3929-3931.	4.0	63
77	Gold(III) Compounds as New Family of Anticancer Drugs. <i>Bioinorganic Chemistry and Applications</i> , 2003, 1, 177-187.	4.1	62
78	Promising <i>in Vitro</i> anti-Alzheimer Properties for a Ruthenium(III) Complex. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 329-332.	2.8	61
79	Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action. <i>Metallomics</i> , 2009, 1, 434.	2.4	60
80	Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. <i>Journal of Biological Inorganic Chemistry</i> , 2010, 15, 573-582.	2.6	60
81	Protein metalation by metal-based drugs: X-ray crystallography and mass spectrometry studies. <i>Chemical Communications</i> , 2017, 53, 11622-11633.	4.1	60
82	Stability of an organometallic ruthenium-ubiquitin adduct in the presence of glutathione: Relevance to antitumour activity. <i>Journal of Inorganic Biochemistry</i> , 2008, 102, 2136-2141.	3.5	59
83	Modeling of copper(II) sites in proteins based on histidyl and glycyl residues. <i>Journal of Inorganic Biochemistry</i> , 2003, 97, 299-307.	3.5	58
84	The combined activation of KCa3.1 and inhibition of Kv11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells. <i>British Journal of Cancer</i> , 2018, 118, 200-212.	6.4	58
85	Unusual Structural Features in the Lysozyme Derivative of the Tetrakis(acetato)chloridodiruthenium(II,III) Complex. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 6172-6175.	13.8	57
86	Ruthenium metalation of proteins: the X-ray structure of the complex formed between NAMI-A and hen egg white lysozyme. <i>Dalton Transactions</i> , 2014, 43, 6128.	3.3	57
87	Cisplatin encapsulation within a ferritin nanocage: a high-resolution crystallographic study. <i>Chemical Communications</i> , 2016, 52, 4136-4139.	4.1	57
88	ESI MS studies highlight the selective interaction of Auranofin with protein free thiols. <i>Dalton Transactions</i> , 2020, 49, 5906-5913.	3.3	57
89	Biological properties of two gold(III) complexes: AuCl ₃ (Hpm) and AuCl ₂ (pm). <i>Journal of Inorganic Biochemistry</i> , 1997, 66, 103-109.	3.5	56
90	Cytotoxicity and DNA binding properties of a chloro glycyllhistidinate gold(III) complex (GHAu). <i>Chemico-Biological Interactions</i> , 2000, 125, 29-38.	4.0	56

#	ARTICLE	IF	CITATIONS
91	Peculiar Features in the Crystal Structure of the Adduct Formed between $\text{cis-Pt}(\text{NH}_3)_2(\text{NH}_3)_2$ and Hen Egg White Lysozyme. <i>Inorganic Chemistry</i> , 2013, 52, 13827-13829.	4.0	56
92	Binding of Antitumor Ruthenium(III) Complexes to Plasma Proteins. <i>Metal-Based Drugs</i> , 2000, 7, 335-342.	3.8	55
93	Speciation of metal-based nanomaterials in human serum characterized by capillary electrophoresis coupled to ICP-MS: a case study of gold nanoparticles. <i>Metallomics</i> , 2015, 7, 1364-1370.	2.4	55
94	^1H -NMR studies on partially and fully reduced 2(4Fe-4S) ferredoxin from <i>Clostridium pasteurianum</i> . <i>FEBS Journal</i> , 1992, 204, 831-839.	0.2	54
95	The Interaction of the Antitumor Complexes $\text{Na}[\text{trans-RuCl}_4(\text{DMSO})(\text{Im})]$ and $\text{Na}[\text{trans-RuCl}_4(\text{DMSO})(\text{Ind})]$ With Apotransferrin: a Spectroscopic Study. <i>Metal-Based Drugs</i> , 1996, 3, 1-9.	3.8	54
96	Simple and rapid physico-chemical methods to examine action of antimalarial drugs with hemin. <i>Life Sciences</i> , 2002, 70, 769-778.	4.3	54
97	Spectroscopic and potentiometric study of the SOD mimic system copper(II)/acetyl-L-histidylglycyl-L-histidylglycine. <i>Journal of Inorganic Biochemistry</i> , 2002, 89, 181-190.	3.5	54
98	Auranofin and its Analogues Show Potent Antimicrobial Activity against Multidrug-Resistant Pathogens: Structure-Activity Relationships. <i>ChemMedChem</i> , 2018, 13, 2448-2454.	3.2	54
99	A Role for Metal-Based Drugs in Fighting COVID-19 Infection? The Case of Auranofin. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1067-1068.	2.8	54
100	Protein-binding Properties of two Antitumour Ru(III) Complexes to Human Apotransferrin and Apolactoferrin. <i>Metal-Based Drugs</i> , 1994, 1, 169-173.	3.8	53
101	Metallo therapeutics for COVID-19. Exploiting metal-based compounds for the discovery of new antiviral drugs. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 39-46.	5.0	53
102	Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: a comparative proteomic study. <i>Oncotarget</i> , 2018, 9, 28042-28068.	1.8	53
103	Formation of titanium(IV) transferrin by reaction of human serum apotransferrin with titanium complexes. <i>FEBS Letters</i> , 1999, 442, 157-161.	2.8	52
104	Interactions of two cytotoxic organotin(IV) compounds with calf thymus DNA. <i>Journal of Inorganic Biochemistry</i> , 2001, 85, 297-300.	3.5	52
105	Molecular structure, solution chemistry and biological properties of the novel $[\text{ImH}][\text{trans-IrCl}_4(\text{Im})(\text{DMSO})]$, (I) and of the orange form of $[(\text{DMSO})_2\text{H}][\text{trans-IrCl}_4(\text{DMSO})_2]$, (II), complexes. <i>Journal of Inorganic Biochemistry</i> , 2003, 95, 37-46.	3.5	52
106	Design, synthesis and characterisation of new chimeric ruthenium-gold complexes as improved cytotoxic agents. <i>Dalton Transactions</i> , 2015, 44, 11067-11076.	3.3	52
107	Solution NMR Structure of a Ligand/Hybrid Cd^{2+} Quadruplex Complex Reveals Rearrangements that Affect Ligand Binding. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 7102-7106.	13.8	52
108	Insights into the Molecular Mechanisms of Protein Platination from a Case Study: The Reaction of Anticancer Platinum(II) Iminoethers with Horse Heart Cytochrome c. <i>Biochemistry</i> , 2007, 46, 12220-12230.	2.5	51

#	ARTICLE	IF	CITATIONS
109	Unravelling the chemical nature of copper cuprizone. Dalton Transactions, 2007, , 2112.	3.3	51
110	Activity of Rat Cytosolic Thioredoxin Reductase Is Strongly Decreased by trans-[Bis(2-amino-5-ylidene)-1,3,4-dithiazol-2-ylidene]iron(II) for a Ruthenium Compound. Journal of Medicinal Chemistry, 2007, 50, 5871-5874.	6.4	50
111	New platinum-oxo complexes as anti-cancer drugs. Synthesis, characterization, release studies from smart hydrogels, evaluation of reactivity with selected proteins and cytotoxic activity in vitro. Journal of Inorganic Biochemistry, 2010, 104, 799-814.	3.5	50
112	Protein metalation by metal-based drugs: reactions of cytotoxic gold compounds with cytochrome c and lysozyme. Journal of Biological Inorganic Chemistry, 2012, 17, 1293-1302.	2.6	50
113	Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c. Journal of Biological Inorganic Chemistry, 2007, 12, 1107-1117.	2.6	49
114	Interactions of gold-based drugs with proteins: crystal structure of the adduct formed between ribonuclease A and a cytotoxic gold(III) compound. Metallomics, 2014, 6, 233-236.	2.4	49
115	Proton NMR studies of the cobalt(II)-metallothionein system. Journal of the American Chemical Society, 1989, 111, 7296-7300.	13.7	48
116	Exploiting Soft and Hard X-Ray Absorption Spectroscopy to Characterize Metalloprotein Interactions: the Binding of [trans-RuCl ₄ (Im)(dimethylsulfoxide)](ImH) (Im = 1H-imidazole) to the Active Site of the Protein. Journal of Inorganic Biochemistry, 2010, 104, 1107-1117.	3.4	48
117	Comparison of the Antiproliferative Activity of Two Antitumour Ruthenium(III) Complexes With Their Apotransferrin and Transferrin-Bound Forms in a Human Colon Cancer Cell Line. Metal-Based Drugs, 1996, 3, 15-23.	3.8	47
118	Oxaliplatin vs. cisplatin: competition experiments on their binding to lysozyme. Dalton Transactions, 2015, 44, 10392-10398.	3.3	47
119	Cytotoxic properties of a new organometallic platinum(II) complex and its gold(I) heterobimetallic derivatives. Dalton Transactions, 2016, 45, 579-590.	3.3	47
120	Synthesis, Structural Characterization, Solution Chemistry, and Preliminary Biological Studies of the Ruthenium(III) Complexes [TzH][trans-RuCl ₄ (Tz) ₂] and [TzH][trans-RuCl ₄ (DMSO)(Tz)]·(DMSO), the Thiazole Analogues of Antitumor ICR and NAMI-A. Inorganic Chemistry, 2004, 43, 3863-3870.	4.0	46
121	Recent progress in the application of analytical techniques to anticancer metalloprotein proteomics. TrAC - Trends in Analytical Chemistry, 2011, 30, 1120-1138.	11.4	46
122	Gold Complexes as Antitumor Agents. , 2004, , 385-424.		46
123	Size dependent biological profiles of PEGylated gold nanorods. Journal of Materials Chemistry B, 2014, 2, 6072-6080.	5.8	45
124	cis-PtI ₂ (NH ₃) ₂ : a reappraisal. Dalton Transactions, 2015, 44, 14896-14905.	3.3	45
125	Determinants for Tight and Selective Binding of a Medicinal Dicarbene Gold(I) Complex to a Telomeric DNA G-Quadruplex: a Joint ESI MS and XRD Investigation. Angewandte Chemie, 2016, 128, 4328-4331.	2.0	45
126	2D ¹ H NMR studies of oxidized 2(Fe ₄ S ₄) ferredoxin from Clostridium pasteurianum. FEBS Letters, 1991, 289, 253-256.	2.8	44

#	ARTICLE	IF	CITATIONS
127	Interactions of gold-based drugs with proteins: the structure and stability of the adduct formed in the reaction between lysozyme and the cytotoxic gold(III) compound Auoxo3. Dalton Transactions, 2014, 43, 17483-17488.	3.3	43
128	Interactions of carboplatin and oxaliplatin with proteins: Insights from X-ray structures and mass spectrometry studies of their ribonuclease A adducts. Journal of Inorganic Biochemistry, 2015, 153, 136-142.	3.5	43
129	Reactions of Auranofin and Its Pseudohalide Derivatives with Serum Albumin Investigated through ESI-Q-TOF MS. Inorganic Chemistry, 2018, 57, 10507-10510.	4.0	43
130	Reactions of Medicinal Gold(III) Compounds With Proteins and Peptides Explored by Electrospray Ionization Mass Spectrometry and Complementary Biophysical Methods. Frontiers in Chemistry, 2020, 8, 581648.	3.6	43
131	Thallium-205 as an NMR probe for the investigation of transferrin. Journal of the American Chemical Society, 1983, 105, 1347-1350.	13.7	42
132	Carbon-13 NMR study of the synergistic anion in transferrins. Inorganic Chemistry, 1986, 25, 1782-1786.	4.0	42
133	Exploring the Reactions of β -Amyloid ($A\beta$) Peptide 1-28 with AlIII and FeIII Ions. Inorganic Chemistry, 2011, 50, 6865-6867.	4.0	42
134	Interaction of anticancer Ru(III) complexes with single stranded and duplex DNA model systems. Dalton Transactions, 2015, 44, 13914-13925.	3.3	42
135	Selection and characterization of a human ovarian cancer cell line resistant to auranofin. Oncotarget, 2017, 8, 96062-96078.	1.8	42
136	The X-ray Structure of the Adduct between NAMI-A and Carbonic Anhydrase Provides Insights into the Reactivity of this Metallodrug with Proteins. ChemMedChem, 2010, 5, 1989-1994.	3.2	40
137	Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand. Journal of Inorganic Biochemistry, 2011, 105, 348-355.	3.5	40
138	The X-ray structure of the complex formed in the reaction between oxaliplatin and lysozyme. Chemical Communications, 2014, 50, 8360.	4.1	40
139	Arsenoplatin-1 Is a Dual Pharmacophore Anticancer Agent. Journal of the American Chemical Society, 2019, 141, 6453-6457.	13.7	40
140	Proteomic analysis of ovarian cancer cell responses to cytotoxic gold compounds. Metallomics, 2012, 4, 307.	2.4	39
141	Cytotoxic activity and protein binding through an unusual oxidative mechanism by an iridium(η^5 -NHC) complex. Chemical Communications, 2015, 51, 3151-3153.	4.1	39
142	Synthesis, molecular structure and solution chemistry of the iridium(III) complex imidazolium [trans(bisimidazole)tetrachloro iridate(III)] (IRIM). Inorganica Chimica Acta, 2001, 312, 74-80.	2.4	38
143	fac-{Ru(CO) ₃ } ²⁺ -Core Complexes and Design of Metal-Based Drugs. Synthesis, Structure, and Reactivity of Ru ^{II} -Thiazole Derivative with Serum Proteins and Absorption/Release Studies with Acryloyl and Silica Hydrogels as Carriers in Physiological Media. Inorganic Chemistry, 2007, 46, 79-92.	4.0	38
144	Reactivity and Biological Properties of a Series of Cytotoxic Pt ₂ (amine) ₂ Complexes, Either <i>cis</i> or <i>trans</i> Configured. Inorganic Chemistry, 2012, 51, 1717-1726.	4.0	38

#	ARTICLE	IF	CITATIONS
145	The molecular mechanisms of antimetastatic ruthenium compounds explored through DICE proteomics. <i>Journal of Inorganic Biochemistry</i> , 2013, 118, 94-99.	3.5	38
146	Study of Ruthenium(II) Complexes with Anticancer Drugs as Ligands. Design of Metal-Based Phototherapeutic Agents. <i>Inorganic Chemistry</i> , 2003, 42, 8038-8052.	4.0	37
147	DOTAP/DOPE and DC-Chol/DOPE lipoplexes for gene delivery studied by circular dichroism and other biophysical techniques. <i>Biophysical Chemistry</i> , 2007, 127, 213-220.	2.8	37
148	Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipyc. <i>Journal of Proteomics</i> , 2014, 103, 103-120.	2.4	37
149	Platinum(II) Complexes with O,S Bidentate Ligands: Biophysical Characterization, Antiproliferative Activity, and Crystallographic Evidence of Protein Binding. <i>Inorganic Chemistry</i> , 2015, 54, 8560-8570.	4.0	37
150	Structure and DNA binding properties of the gold(III) complex [AuCl ₂ (esal)]. <i>Inorganica Chimica Acta</i> , 1999, 285, 309-312.	2.4	35
151	Peculiar mechanistic and structural features of the carboplatin-cytochrome c system revealed by ESI-MS analysis. <i>Journal of Biological Inorganic Chemistry</i> , 2008, 13, 755-764.	2.6	35
152	PtI ₂ (DACH), the iodo analogue of oxaliplatin as a candidate for colorectal cancer treatment: chemical and biological features. <i>Dalton Transactions</i> , 2017, 46, 3311-3317.	3.3	35
153	Interaction of a gold(I) dicarbene anticancer drug with human telomeric DNA C-quadruplex: solution and computationally aided X-ray diffraction analysis. <i>Dalton Transactions</i> , 2018, 47, 16132-16138.	3.3	35
154	A Fluorescent Silver(I) Carbene Complex with Anticancer Properties: Synthesis, Characterization, and Biological Studies. <i>ChemMedChem</i> , 2018, 14, 182-188.	3.2	35
155	The copper(II) coordination abilities of three novel cyclic tetrapeptides with -His-Xaa-His- motif. <i>Journal of Inorganic Biochemistry</i> , 2007, 101, 452-460.	3.5	34
156	Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: Solution behavior, reactions with model proteins, antiproliferative properties. <i>Journal of Inorganic Biochemistry</i> , 2012, 108, 123-127.	3.5	34
157	Novel platinum(II) compounds with O,S bidentate ligands: synthesis, characterization, antiproliferative properties and biomolecular interactions. <i>Dalton Transactions</i> , 2014, 43, 3072-3086.	3.3	34
158	NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3.1 channels. <i>Dalton Transactions</i> , 2014, 43, 12150-12155.	3.3	34
159	Structural Characterization of a Gold/Serum Albumin Complex. <i>Inorganic Chemistry</i> , 2019, 58, 10616-10619.	4.0	34
160	Spectral characterization of ruthenium(III) transferrin. <i>Journal of Inorganic Biochemistry</i> , 1993, 49, 79-82.	3.5	33
161	Cytotoxicity, DNA Damage, and Cell Cycle Perturbations Induced by Two Representative Gold(III) Complexes in Human Leukemic Cells With Different Cisplatin Sensitivity. <i>Oncology Research</i> , 2001, 12, 361-370.	1.5	33
162	Protein Recognition of Gold-Based Drugs: 3D Structure of the Complex Formed When Lysozyme Reacts with Aubipy ^c . <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 1110-1113.	2.8	33

#	ARTICLE	IF	CITATIONS
163	Molecular Recognition of Metal Complexes by DNA: A Comparative Study of the Interactions of the Parent Complexes [PtCl(TERPY)]Cl and [AuCl(TERPY)]Cl ₂ with Double Stranded DNA. <i>Bioinorganic Chemistry and Applications</i> , 2005, 3, 239-253.	4.1	32
164	Cytotoxic Profile and Peculiar Reactivity with Biomolecules of a Novel “Rule-Breaker” Iridoplatinum(II) Complex. <i>ACS Medicinal Chemistry Letters</i> , 2010, 1, 381-385.	2.8	32
165	Protein Targets for Anticancer Gold Compounds: Mechanistic Inferences. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2011, 11, 929-939.	1.7	32
166	Medicinal gold compounds form tight adducts with the copper chaperone Atox-1: biological and pharmacological implications. <i>Chemical Communications</i> , 2012, 48, 11623.	4.1	32
167	Metal-Based Compounds as Prospective Antileishmanial Agents: Inhibition of Trypanothione Reductase by Selected Gold Complexes. <i>ChemMedChem</i> , 2013, 8, 1634-1637.	3.2	32
168	A first-in-class and a fished out anticancer platinum compound: cis-[PtCl ₂ (NH ₃) ₃] ₂ and cis-[PtCl ₂ (NH ₃) ₃] ₂ compared for their reactivity towards DNA model systems. <i>Dalton Transactions</i> , 2016, 45, 8587-8600.	3.3	32
169	Structure-activity relationships in a series of auranofin analogues showing remarkable antiproliferative properties. <i>Journal of Inorganic Biochemistry</i> , 2020, 208, 111079.	3.5	32
170	Investigation of the effects of copper ions on protein aggregation using a model system. <i>Cellular and Molecular Life Sciences</i> , 2004, 61, 982-991.	5.4	31
171	The copper(II) binding properties of the cyclic peptide c(HGHK). <i>Journal of Inorganic Biochemistry</i> , 2004, 98, 2016-2021.	3.5	31
172	Proteomic and Metallomic Strategies for Understanding the Mode of Action of Anticancer Metallodrugs. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2010, 10, 324-337.	1.7	31
173	The X-ray structure of the primary adducts formed in the reaction between cisplatin and cytochrome c. <i>Chemical Communications</i> , 2015, 51, 2559-2561.	4.1	31
174	Mechanistic Insights Into the Anticancer Properties of the Auranofin Analog Au(PEt ₃)I: A Theoretical and Experimental Study. <i>Frontiers in Chemistry</i> , 2020, 8, 812.	3.6	31
175	Outstanding plasmodicidal properties within a small panel of metallic compounds: Hints for the development of new metal-based antimalarials. <i>Journal of Inorganic Biochemistry</i> , 2009, 103, 310-312.	3.5	30
176	2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds. <i>Molecular BioSystems</i> , 2012, 8, 985-993.	2.9	30
177	Mass spectrometry and metallomics: A general protocol to assess stability of metallodrug-protein adducts in bottom-up MS experiments. <i>Talanta</i> , 2017, 167, 30-38.	5.5	30
178	Solution studies of the antitumor complex dichloro 1,2-propylenediaminetetraacetate ruthenium (III) and of its interactions with proteins. <i>Journal of Inorganic Biochemistry</i> , 1998, 71, 45-51.	3.5	29
179	New Copper(II)/Cyclic Tetrapeptide System That Easily Oxidizes to Copper(III) under Atmospheric Oxygen. <i>Inorganic Chemistry</i> , 2007, 46, 10038-10040.	4.0	29
180	Mechanistic studies on two dinuclear organogold(III) compounds showing appreciable antiproliferative properties and a high redox stability. <i>Metallomics</i> , 2011, 3, 1318.	2.4	29

#	ARTICLE	IF	CITATIONS
181	Interactions between Anticancer <i>trans</i> -Platinum Compounds and Proteins: Crystal Structures and ESI-MS Spectra of Two Protein Adducts of <i>trans</i> -(Dimethylamino)(methylamino)dichloridoplatinum(II). <i>Inorganic Chemistry</i> , 2014, 53, 7806-7808.	4.0	29
182	New gold carbene complexes as candidate anticancer agents. <i>BioMetals</i> , 2016, 29, 905-911.	4.1	29
183	Ru-Based CO releasing molecules with azole ligands: interaction with proteins and the CO release mechanism disclosed by X-ray crystallography. <i>Dalton Transactions</i> , 2017, 46, 9621-9629.	3.3	29
184	Protein interactions of dirhodium tetraacetate: a structural study. <i>Dalton Transactions</i> , 2020, 49, 2412-2416.	3.3	29
185	Structural Features of a New Dinuclear Platinum(II) Complex with Significant Antiproliferative Activity. <i>Inorganic Chemistry</i> , 2003, 42, 6166-6168.	4.0	28
186	X-ray absorption spectroscopy studies of the adducts formed between cytotoxic gold compounds and two major serum proteins. <i>Journal of Biological Inorganic Chemistry</i> , 2011, 16, 491-499.	2.6	28
187	Chemistry and biology of three representative gold(III) compounds as prospective anticancer agents. <i>Inorganica Chimica Acta</i> , 2012, 393, 115-124.	2.4	28
188	Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(II) compounds with sulfur and phosphorus donors. <i>Dalton Transactions</i> , 2011, 40, 2006.	3.3	27
189	Butyltin(IV) Benzoates: Inhibition of Thioredoxin Reductase, Tumor Cell Growth Inhibition, and Interactions with Proteins. <i>ChemMedChem</i> , 2013, 8, 256-264.	3.2	27
190	Selected cytotoxic gold compounds cause significant inhibition of 20S proteasome catalytic activities. <i>Journal of Inorganic Biochemistry</i> , 2014, 141, 79-82.	3.5	27
191	Rapid purification of gold nanorods for biomedical applications. <i>MethodsX</i> , 2014, 1, 118-123.	1.6	27
192	Gold(III) complexes with hydroxyquinoline, aminoquinoline and quinoline ligands: Synthesis, cytotoxicity, DNA and protein binding studies. <i>Journal of Inorganic Biochemistry</i> , 2015, 153, 339-345.	3.5	27
193	{Ru(CO) _x }-Core complexes with benzimidazole ligands: synthesis, X-ray structure and evaluation of anticancer activity in vivo. <i>Dalton Transactions</i> , 2017, 46, 3025-3040.	3.3	27
194	Kinetic studies on metal removal from transferrins by pyrophosphate. Investigation on iron(III) and manganese(III) derivatives. <i>Inorganic Chemistry</i> , 1988, 27, 2405-2409.	4.0	26
195	Proton NMR spectra of the Co ₄ S ₁₁ cluster in metallothioneins: a theoretical model. <i>Journal of the American Chemical Society</i> , 1989, 111, 7300-7303.	13.7	26
196	Gold(III) complexes as a new family of cytotoxic and antitumor agents. <i>Expert Review of Anticancer Therapy</i> , 2002, 2, 337-346.	2.4	26
197	Structure-Function Relationships within Keppler-Type Antitumor Ruthenium(III) Complexes: The Case of 2-Aminothiazolium[trans-tetrachlorobis(2-aminothiazole)ruthenate(III)]. <i>Inorganic Chemistry</i> , 2005, 44, 4897-4899.	4.0	26
198	Impact of ring size on the copper(II) coordination abilities of cyclic tetrapeptides. <i>Journal of Inorganic Biochemistry</i> , 2009, 103, 813-817.	3.5	26

#	ARTICLE	IF	CITATIONS
199	Antiproliferative properties and biomolecular interactions of three Pd(II) and Pt(II) complexes. Journal of Inorganic Biochemistry, 2016, 165, 1-6.	3.5	26
200	Cisplatin Binding Sites in Human H-Chain Ferritin. Inorganic Chemistry, 2017, 56, 9064-9070.	4.0	26
201	The cisplatin/serum albumin system: A reappraisal. Inorganica Chimica Acta, 2019, 495, 118983.	2.4	26
202	Synthesis, spectroscopic and DFT structural characterization of two novel ruthenium(III) oxidam complexes. In vivo evaluation of anti-inflammatory and gastric damaging activities. Journal of Inorganic Biochemistry, 2014, 134, 25-35.	3.5	25
203	{Ru(CO) _x }-core complexes with selected azoles: Synthesis, X-ray structure, spectroscopy, DFT analysis and evaluation of cytotoxic activity against human cancer cells. Polyhedron, 2014, 81, 227-237.	2.2	24
204	Gold compounds as cysteine protease inhibitors: perspectives for pharmaceutical application as antiparasitic agents. BioMetals, 2017, 30, 313-320.	4.1	24
205	The NAMI A " human ferritin system: a biophysical characterization. Dalton Transactions, 2018, 47, 11429-11437.	3.3	24
206	Induction of a Four-Way Junction Structure in the DNA Palindromic Hexanucleotide 5'-GGG(CGTACG)GGG by a Mononuclear Platinum Complex. Angewandte Chemie - International Edition, 2019, 58, 9378-9382.	13.8	24
207	Gold complexes in the treatment of rheumatoid arthritis. Metal Ions in Biological Systems, 2004, 41, 279-304.	0.4	24
208	Evidence of a metal-synergistic anion bond in thallium(III) transferrin. Inorganic Chemistry, 1988, 27, 761-762.	4.0	23
209	Solution Chemistry and DNA Binding Properties of MEN 10755, A Novel Disaccharide Analogue of Doxorubicin. Bioorganic and Medicinal Chemistry, 2001, 9, 1815-1825.	3.0	23
210	Structure of a Terbium(III)-Quinizarine Complex: The First Crystallographic Model for Metalloanthracyclines. Inorganic Chemistry, 2003, 42, 3157-3159.	4.0	23
211	Water-soluble Ru(II)- and Ru(III)-halide-PTA complexes (PTA = 1,3,5-triaza-7-phosphaadamantane): Chemical and biological properties. Journal of Inorganic Biochemistry, 2016, 160, 180-188.	3.5	23
212	Proteomics as a tool to disclose the cellular and molecular mechanisms of selected anticancer gold compounds. Coordination Chemistry Reviews, 2021, 438, 213905.	18.8	23
213	Metal-Induced Conformational Heterogeneity of Transferrins: A Spectroscopic Study of Indium(III) and Other Metal(III)-Substituted Transferrins. Biochemical and Biophysical Research Communications, 1995, 206, 161-170.	2.1	22
214	Interactions of selected gold(III) complexes with DNA G quadruplexes. Dalton Transactions, 2015, 44, 3633-3639.	3.3	22
215	Organogold(III) compounds as experimental anticancer agents: chemical and biological profiles. BioMetals, 2016, 29, 863-872.	4.1	22
216	11. NON-COVALENT METALLO-DRUGS: USING SHAPE TO TARGET DNA AND RNA JUNCTIONS AND OTHER NUCLEIC ACID STRUCTURES. , 2018, 18, 303-324.		22

#	ARTICLE	IF	CITATIONS
217	A case of extensive protein platination: the reaction of lysozyme with a Pt(II)-terpyridine complex. Dalton Transactions, 2018, 47, 8716-8723.	3.3	22
218	Reactions of cisplatin and cis-[PtI2(NH3)2] with molecular models of relevant protein sidechains: A comparative analysis. Journal of Inorganic Biochemistry, 2020, 209, 111096.	3.5	22
219	pH-dependent properties of cobalt(II) carboxypeptidase A-inhibitor complexes. Biochemistry, 1992, 31, 3840-3846.	2.5	21
220	Coordination compounds and life processes. Coordination Chemistry Reviews, 1992, 120, 163-192.	18.8	21
221	A two-dimensional NMR study of Co(II)-7 rabbit liver metallothionein. FEBS Journal, 1993, 211, 235-240.	0.2	21
222	Structural effects of titanium citrate on the human erythrocyte membrane. Journal of Inorganic Biochemistry, 2005, 99, 764-770.	3.5	21
223	Solution Behaviour and Biomolecular Interactions of Two Cytotoxic <i>trans</i> -Platinum(II) Complexes Bearing Aliphatic Amine Ligands. Chemistry - A European Journal, 2009, 15, 9139-9146.	3.3	21
224	Proanthocyanidin glycosides from the leaves of <i>Quercus ilex</i> L. (Fagaceae). Tetrahedron Letters, 2009, 50, 1771-1776.	1.4	21
225	Effects of two representative antitumor ruthenium(III) complexes on thermal denaturation profiles of DNA. Inorganica Chimica Acta, 2000, 303, 283-286.	2.4	20
226	Solution NMR Structure of a Ligand/Hybrid $\text{C}_{2}\text{A}^{2+}\text{C}_{2}\text{G}^{2+}\text{C}_{2}\text{G}^{2+}\text{C}_{2}\text{G}^{2+}$ Quadruplex Complex Reveals Rearrangements that Affect Ligand Binding. Angewandte Chemie, 2017, 129, 7208-7212.	2.0	20
227	Redox proteome analysis of auranofin exposed ovarian cancer cells (A2780). Redox Biology, 2022, 52, 102294.	9.0	20
228	Selective interaction of ferricyanide with cluster I of <i>Clostridium pasteurianum</i> 2[Fe4 S4] ferredoxin. FEBS Letters, 1993, 332, 268-272.	2.8	19
229	The disaccharide anthracycline MEN 10755 binds human serum albumin to a non-classical drug binding site. Bioorganic and Medicinal Chemistry, 2002, 10, 3425-3430.	3.0	19
230	Crystallographic evidence for decomposition of dimethylformamide in the presence of ruthenium(III) chloride. Inorganica Chimica Acta, 2003, 355, 420-423.	2.4	19
231	Selected gold compounds cause pronounced inhibition of <i>Falcipain 2</i> and effectively block <i>P. falciparum</i> growth in vitro. Journal of Inorganic Biochemistry, 2011, 105, 1576-1579.	3.5	19
232	The fate of differently functionalized gold nanorods in human serum: A response from capillary electrophoresis-inductively coupled plasma mass spectrometry. Journal of Chromatography A, 2017, 1499, 222-225.	3.7	19
233	Synthesis and Mode of Action Studies on Iridium(I)-NHC Anticancer Drug Candidates. European Journal of Inorganic Chemistry, 2018, 2018, 2461-2470.	2.0	19
234	A 1H NMR study of the complex of cobalt(II) with 2,5,8,11-tetramethyl-2,5,8,11-tetraazadodecane in aerated aqueous solutions. Inorganica Chimica Acta, 1995, 235, 5-8.	2.4	18

#	ARTICLE	IF	CITATIONS
235	The C2 variant of human serum transferrin retains the iron binding properties of the native protein. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2005, 1741, 264-270.	3.8	18
236	Short-chain oligopeptides with copper(II) binding properties: The impact of specific structural modifications on the copper(II) coordination abilities. <i>Journal of Inorganic Biochemistry</i> , 2009, 103, 678-688.	3.5	18
237	Anticancer Ruthenium(III) Complex KP1019 Interferes with ATP-Dependent Ca^{2+} Translocation by Sarco-Endoplasmic Reticulum Ca^{2+} -ATPase (SERCA). <i>ChemMedChem</i> , 2014, 9, 1660-1664.	3.2	18
238	A water 17O NMR study of the pH dependent properties of superoxide dismutase. <i>Biochemical and Biophysical Research Communications</i> , 1981, 101, 577-583.	2.1	17
239	A Novel Class of Peptides with Facilitating Action on Neuronal Nicotinic Receptors of Rat Chromaffin Cells in Vitro: Functional and Molecular Dynamics Studies. <i>Molecular Pharmacology</i> , 2002, 61, 43-54.	2.3	17
240	Spectrophotometric and ESI-MS/HPLC studies reveal a common mechanism for the reaction of various artemisinin analogues with hemin. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 4055-4057.	2.2	17
241	Cell and Cell-Free Mechanistic Studies on Two Gold(III) Complexes with Proven Antitumor Properties. <i>European Journal of Inorganic Chemistry</i> , 2017, 2017, 1737-1744.	2.0	17
242	The leading established metal-based drugs: a revisitation of their relevant physico-chemical data. <i>BioMetals</i> , 2019, 32, 813-817.	4.1	17
243	NMR reveals the metabolic changes induced by auranofin in A2780 cancer cells: evidence for glutathione dysregulation. <i>Dalton Transactions</i> , 2021, 50, 6349-6355.	3.3	17
244	Trans- cis -[RuCl ₂ (DMSO) ₂ (2-amino-5-methyl-thiazole) ₂], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B. <i>Journal of Inorganic Biochemistry</i> , 2010, 104, 111-117.	3.5	16
245	Biological Properties of IRIM, the Iridium(III) Analogue of (Imidazolium (Bisimidazole)) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 342	3.8	16
246	Spectral characterization of vanadium-transferrin systems. <i>Journal of Inorganic Biochemistry</i> , 1985, 25, 57-60.	3.5	15
247	Structural evidences for a secondary gold binding site in the hydrophobic box of lysozyme. <i>BioMetals</i> , 2015, 28, 745-754.	4.1	15
248	Elucidating the reactivity of Pt(II) complexes with (O,S) bidentate ligands towards DNA model systems. <i>Journal of Inorganic Biochemistry</i> , 2016, 160, 198-209.	3.5	15
249	The metal-binding properties of ovotransferrin. An investigation of cobalt(II) derivatives.. <i>Journal of Biological Chemistry</i> , 1986, 261, 1139-1146.	3.4	15
250	Cytotoxic effects of gold(III) complexes on established human tumor cell lines sensitive and resistant to cisplatin. <i>Anti-cancer Drug Design</i> , 1998, 13, 67-80.	0.3	15
251	¹ H NMR detection of CoOH ₂ . dblharw. CoOH interconversions in high-spin cobalt(II) complexes. <i>Inorganic Chemistry</i> , 1982, 21, 3426-3429.	4.0	14
252	Cobalt(II) as an NMR probe for the investigation of the coordination sites of conalbumin. <i>FEBS Journal</i> , 1984, 141, 375-378.	0.2	14

#	ARTICLE	IF	CITATIONS
253	Alkyne Functionalization of a Photoactivated Ruthenium Polypyridyl Complex for Click-Enabled Serum Albumin Interaction Studies. <i>Inorganic Chemistry</i> , 2020, 59, 7710-7720.	4.0	14
254	Effect of nonsynergistic anions on copper transferrin. <i>Inorganic Chemistry</i> , 1988, 27, 1081-1086.	4.0	13
255	The pH dependent properties of metallothioneins: a comparative study. <i>BioMetals</i> , 1997, 10, 303-313.	4.1	13
256	Tuning the interactions of PEG-coated gold nanorods with BSA and model proteins through insertion of amino or carboxylate groups. <i>Journal of Inorganic Biochemistry</i> , 2015, 150, 120-125.	3.5	13
257	Cisplatin and its dibromido analogue: a comparison of chemical and biological profiles. <i>BioMetals</i> , 2016, 29, 535-542.	4.1	13
258	Na/K-ATPase as a target for anticancer metal based drugs: insights into molecular interactions with selected gold(III) complexes. <i>Metallomics</i> , 2017, 9, 292-300.	2.4	13
259	Reactions of a tetranuclear Pt-thiosemicarbazone complex with model proteins. <i>Journal of Inorganic Biochemistry</i> , 2018, 181, 11-17.	3.5	13
260	New platinum(II) and palladium(II) complexes with substituted terpyridine ligands: synthesis and characterization, cytotoxicity and reactivity towards biomolecules. <i>BioMetals</i> , 2019, 32, 33-47.	4.1	13
261	Anticancer effects against colorectal cancer models of chloro(triethylphosphine)gold(I) encapsulated in PLGA-PEG nanoparticles. <i>BioMetals</i> , 2021, 34, 867-879.	4.1	13
262	Transferrin: From Inorganic Biochemistry to Medicine. <i>Metal-Based Drugs</i> , 1994, 1, 161-167.	3.8	12
263	Evidence that the antiproliferative effects of auranofin in <i>Saccharomyces cerevisiae</i> arise from inhibition of mitochondrial respiration. <i>International Journal of Biochemistry and Cell Biology</i> , 2015, 65, 61-71.	2.8	12
264	ESI-MS studies of the reactions of novel platinum(II) complexes containing O,O'-chelated acetylacetonate and sulfur ligands with selected model proteins. <i>BioMetals</i> , 2017, 30, 609-614.	4.1	12
265	Structural and solution chemistry, antiproliferative effects, and serum albumin binding of three pseudohalide derivatives of auranofin. <i>BioMetals</i> , 2019, 32, 939-948.	4.1	12
266	Protein metalation by two structurally related gold(I) carbene complexes: An ESI MS study. <i>Inorganica Chimica Acta</i> , 2021, 520, 120297.	2.4	12
267	¹ H-NMR Investigation of the Interaction of the Amino Terminal Domain of the LexA Repressor with a Synthetic Half-Operator. <i>Journal of Biomolecular Structure and Dynamics</i> , 1991, 9, 447-461.	3.5	11
268	Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 631-641.	3.0	11
269	Nitrate as a probe of cytochrome c surface: Crystallographic identification of crucial "hot spots" for protein-protein recognition. <i>Journal of Inorganic Biochemistry</i> , 2014, 135, 58-67.	3.5	11
270	Inhibition of Na ⁺ /K ⁺ -ATPase and cytotoxicity of a few selected gold(III) complexes. <i>Journal of Inorganic Biochemistry</i> , 2014, 140, 228-235.	3.5	11

#	ARTICLE	IF	CITATIONS
271	Reactions of model proteins with aurothiomalate, a clinically established gold(I) drug: The comparison with auranofin. <i>Journal of Inorganic Biochemistry</i> , 2015, 149, 102-107.	3.5	11
272	Synthesis, DNA binding studies, and antiproliferative activity of novel Pt(II)-complexes with an L-alanyl-based ligand. <i>Journal of Inorganic Biochemistry</i> , 2020, 203, 110868.	3.5	11
273	On the Different Mode of Action of Au(I)/Ag(I)-NHC Bis-Anthracenyl Complexes Towards Selected Target Biomolecules. <i>Molecules</i> , 2020, 25, 5446.	3.8	11
274	The metal-binding properties of ovotransferrin. An investigation of cobalt(II) derivatives. <i>Journal of Biological Chemistry</i> , 1986, 261, 1139-46.	3.4	11
275	In Vitro Anti-SARS-CoV-2 Activity of Selected Metal Compounds and Potential Molecular Basis for Their Actions Based on Computational Study. <i>Biomolecules</i> , 2021, 11, 1858.	4.0	11
276	Interaction of phosphate and pyrophosphate with cobalt(II) carboxypeptidase. <i>Inorganic Chemistry</i> , 1990, 29, 202-205.	4.0	10
277	Reactions of metallodrugs with proteins: selective binding of phosphane-based platinum(ii) dichlorides to horse heart cytochrome c probed by ESI MS coupled to enzymatic cleavage. <i>Metallomics</i> , 2011, 3, 987-990.	2.4	10
278	Proteomic analysis of the cytotoxic effects induced by the organogold(Au^{III}) complex Aubipy C in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication. <i>Molecular BioSystems</i> , 2015, 11, 1653-1667.	2.9	10
279	Diruthenium Diacetate Catalysed Aerobic Oxidation of Hydroxylamines and Improved Chemoselectivity by Immobilisation to Lysozyme. <i>ChemCatChem</i> , 2017, 9, 4225-4230.	3.7	10
280	The electrochemical profiles of Auranofin and Aubipyc, two representative medicinal gold compounds: A comparative study. <i>Journal of Inorganic Biochemistry</i> , 2019, 198, 110714.	3.5	10
281	Antiproliferative Properties of a Few Auranofin-Related Gold(I) and Silver(I) Complexes in Leukemia Cells and their Interferences with the Ubiquitin Proteasome System. <i>Molecules</i> , 2020, 25, 4454.	3.8	10
282	Kinetic and structural analysis of the inactivation of urease by mixed-ligand phosphine halide Ag(I) complexes. <i>Journal of Inorganic Biochemistry</i> , 2021, 218, 111375.	3.5	10
283	Medicinal Au(I) compounds targeting urease as prospective antimicrobial agents: unveiling the structural basis for enzyme inhibition. <i>Dalton Transactions</i> , 2021, 50, 14444-14452.	3.3	10
284	CD and EXAFS study of the interaction between phosvitin and copper(II) ions. <i>Journal of Inorganic Biochemistry</i> , 1988, 34, 221-239.	3.5	9
285	EXAFS studies on the oxalate adduct of iron transferrin. <i>Journal of Inorganic Biochemistry</i> , 1992, 46, 1-6.	3.5	9
286	Au $_2$ trien: a dinuclear gold(III) complex with unprecedented structural features. <i>Chemical Communications</i> , 2002, , 612-613.	4.1	9
287	Effects of chronic treatment with sodium tetrachloroaurate(III) in mice and membrane models. <i>Journal of Inorganic Biochemistry</i> , 2004, 98, 2080-2086.	3.5	9
288	The Influence of Auranofin, a Clinically Established Antiarthritic Gold Drug, on Bone Metabolism: Analysis of Its Effects on Human Multipotent Adipose-Derived Stem Cells, Taken as a Model. <i>Chemistry and Biodiversity</i> , 2008, 5, 1513-1520.	2.1	9

#	ARTICLE	IF	CITATIONS
289	Gold complexes as antitumor agents. <i>Metal Ions in Biological Systems</i> , 2004, 42, 385-424.	0.4	9
290	EXAFS investigation on the iron(III) binding sites of hen phosvitin. <i>Inorganic Chemistry</i> , 1990, 29, 124-127.	4.0	8
291	EXAFS studies of Fe(III)-phosvitin at high metal to protein ratios. <i>BioMetals</i> , 1994, 7, 104-8.	4.1	8
292	Synthesis, characterization and DNA interactions of [Pt ₃ (TPyMT)Cl ₃], the trinuclear platinum(II) complex of the TPyMT ligand. <i>Journal of Inorganic Biochemistry</i> , 2018, 183, 101-106.	3.5	8
293	Controlling with light the interaction between <i>trans</i> -tetrapyrrolyl ruthenium complexes and an oligonucleotide. <i>Dalton Transactions</i> , 2018, 47, 507-516.	3.3	8
294	Au ₂ phen and Au ₂ oxo ₆ , Two Dinuclear Oxo-Bridged Gold(III) Compounds, Induce Apoptotic Signaling in Human Ovarian A2780 Cancer Cells. <i>Biomedicines</i> , 2021, 9, 871.	3.2	8
295	Reactions with Proteins of Three Novel Anticancer Platinum(II) Complexes Bearing N-Heterocyclic Ligands. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10551.	4.1	8
296	Chlorido and bromido oxaliplatin analogues as potential agents for CRC treatment: Solution behavior, protein binding and cytotoxicity evaluation. <i>Inorganica Chimica Acta</i> , 2018, 470, 318-324.	2.4	8
297	Auranofin and its analogs as prospective agents for the treatment of colorectal cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 1-14.	2.1	8
298	The effects of two gold-N-heterocyclic carbene (NHC) complexes in ovarian cancer cells: a redox proteomic study. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 809-823.	2.3	8
299	¹ H NMR studies on lanthanides substituted transferrins. <i>Journal of Inorganic Biochemistry</i> , 1991, 42, 185-190.	3.5	7
300	Antiplasmodial Effects of a few Selected Natural Flavonoids and their Modulation of Artemisinin Activity. <i>Natural Product Communications</i> , 2008, 3, 1934578X0800301.	0.5	7
301	Design and solid phase synthesis of new DOTA conjugated (+)-biotin dimers planned to develop molecular weight-tuned avidin oligomers. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 3988-4001.	2.8	7
302	The influence of oxo-bridged binuclear gold(III) complexes on Na/K-ATPase activity: a joint experimental and theoretical approach. <i>Journal of Biological Inorganic Chemistry</i> , 2017, 22, 819-832.	2.6	7
303	[Au(9- <i>methyle</i> caffein-8-ylidene)] ²⁺ /DNA Tel23 System: Solution, Computational, and Biological Studies. <i>Chemistry - A European Journal</i> , 2017, 23, 13784-13791.	3.3	7
304	Arsenoplatin-Ferritin Nanocage: Structure and Cytotoxicity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1874.	4.1	7
305	Ytterbium(III) as a CD probe for the investigation of the metal binding sites of transferrins. <i>Inorganica Chimica Acta</i> , 1986, 124, L15-L17.	2.4	6
306	Frontiers in 2D NMR of paramagnetic metalloproteins. <i>Applied Magnetic Resonance</i> , 1993, 4, 461-476.	1.2	6

#	ARTICLE	IF	CITATIONS
307	Reaction with Proteins of a Five-Coordinate Platinum(II) Compound. <i>International Journal of Molecular Sciences</i> , 2019, 20, 520.	4.1	6
308	Conjugates of Gold Nanoparticles and Antitumor Gold(III) Complexes as a Tool for Their AFM and SERS Detection in Biological Tissue. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6306.	4.1	6
309	Direct detection of iron clusters in L ferritins through ESI-MS experiments. <i>Dalton Transactions</i> , 2021, 50, 16464-16467.	3.3	6
310	Comparative reactivity of medicinal gold($\text{Au}(\text{I})$) compounds with the cyclic peptide vasopressin and its diselenide analogue. <i>Dalton Transactions</i> , 2021, 50, 17487-17490.	3.3	6
311	Influence of cis- and trans-diamminedichloroplatinum(II) binding on the helix-coil transition of DNAs with different GC content. <i>Inorganica Chimica Acta</i> , 1998, 275-276, 510-514.	2.4	5
312	Potential antitumor gold drugs: DFT and XANES studies of local atomic and electronic structure. <i>Journal of Physics: Conference Series</i> , 2009, 190, 012210.	0.4	5
313	Potent in vitro antiproliferative properties for a triplatinum cluster toward triple negative breast cancer cells. <i>Journal of Inorganic Biochemistry</i> , 2016, 163, 318-322.	3.5	5
314	Leaf Decoction of <i>Carica papaya</i> Combined with Artesunate Prevents Recrudescence in <i>Plasmodium berghei</i> -Infected Mice. <i>Planta Medica</i> , 2019, 85, 934-940.	1.3	5
315	Native mass spectrometry of human carbonic anhydrase I and its inhibitor complexes. <i>Journal of Biological Inorganic Chemistry</i> , 2020, 25, 979-993.	2.6	5
316	The first step of arsenoplatin-1 aggregation in solution unveiled by solving the crystal structure of its protein adduct. <i>Dalton Transactions</i> , 2021, 50, 68-71.	3.3	5
317	Ruthenium(II) 1,4,7-trithiacyclononane complexes of curcumin and bisdemethoxycurcumin: Synthesis, characterization, and biological activity. <i>Journal of Inorganic Biochemistry</i> , 2021, 218, 111387.	3.5	5
318	Reactions of Arsenoplatin-1 with Protein Targets: A Combined Experimental and Theoretical Study. <i>Inorganic Chemistry</i> , 2022, 61, 3240-3248.	4.0	5
319	Cobalt(II) as a probe of the metal binding sites of transferrins. <i>Inorganica Chimica Acta</i> , 1990, 174, 137-140.	2.4	4
320	Comparative Analysis of $[\text{Au}(\text{en})_2]^{3+}$ and $[\text{Pt}(\text{en})_2]^{2+}$ non Covalent Binding to Calf Thymus DNA. <i>Metal-Based Drugs</i> , 2000, 7, 253-256.	3.8	4
321	The reaction of artemisinin with hemin: a further insight into the mechanism. <i>Inorganica Chimica Acta</i> , 2004, 357, 4602-4606.	2.4	4
322	Reactions of cytotoxic metallodrugs with lysozyme in pure DMSO explored through UV-Vis absorption spectroscopy and ESI MS. <i>BioMetals</i> , 2015, 28, 425-430.	4.1	4
323	Interactions of the organogold(III) compound Aubipyc with the copper chaperone Atox1: a joint mass spectrometry and circular dichroism investigation. <i>BioMetals</i> , 2015, 28, 1079-1085.	4.1	4
324	Induction of a Four-Way Junction Structure in the DNA Palindromic Hexanucleotide $5'-(\text{CGTACG})_3-3'$ by a Mononuclear Platinum Complex. <i>Angewandte Chemie</i> , 2019, 131, 9478-9482.	2.0	4

#	ARTICLE	IF	CITATIONS
325	Cyclodextrin Inclusion Complexes of Auranofin and Its Iodido Analog: A Chemical and Biological Study. <i>Pharmaceutics</i> , 2021, 13, 727.	4.5	4
326	¹ H NMR studies on reduced high potential iron protein (HIPIP) from <i>Chromatium Vinosum</i> . <i>Applied Magnetic Resonance</i> , 1993, 4, 477-489.	1.2	3
327	Transferrin: A Natural Carrier for Metal Ions and Drugs. , 1997, , 349-361.		3
328	Role of aminoacidic residues inside active sites of metalloproteins. <i>Pure and Applied Chemistry</i> , 1988, 60, 1261-1266.	1.9	3
329	A ¹ H NMR study of cobalt(II) arsanilazocarboxypeptidase A. <i>Journal of Inorganic Biochemistry</i> , 1989, 35, 225-230.	3.5	2
330	EXAFS studies on copper transferrin. <i>Journal of Inorganic Biochemistry</i> , 1992, 48, 33-40.	3.5	2
331	The pH dependent spectral properties of <i>Clostridium pasteurianum</i> 2[Fe4S4] ferredoxin. <i>FEBS Letters</i> , 1994, 350, 41-45.	2.8	2
332	(S)-(+)-2-[2-(Biphenyl-2-yl)-1-methylethyl]-4,5-dihydro-1H-imidazolium hydrogen oxalate. <i>Acta Crystallographica Section E: Structure Reports Online</i> , 2005, 61, o2376-o2378.	0.2	2
333	A multi-technique approach to predicting the molecular structure of cuprizone in the gas phase and in the crystalline state. <i>CrystEngComm</i> , 2008, , .	2.6	2
334	Ruthenium-Sulfoxide Complexes with a Specific Antimetastatic Activity. , 1997, , 457-466.		2
335	Platinum-Based Anticancer Drugs: Unveiling Novel Mechanisms of Action of Conventional Metallo drugs for Improved Therapies. <i>Current Topics in Medicinal Chemistry</i> , 2021, 21, .	2.1	2
336	Protein targets for anticancer metal based drugs. , 2022, , .		1
337	Computationally enhanced X-ray diffraction analysis of a gold(III) complex interacting with the human telomeric DNA G-quadruplex. Unravelling non-unique ligand positioning. <i>International Journal of Biological Macromolecules</i> , 2022, 211, 506-513.	7.5	1
338	Interaction of the antitumour ruthenium(III) complex trans-indazolium[tetrachlorobisindazolruthenate(III)] with apotransferrin. <i>Journal of Inorganic Biochemistry</i> , 1993, 51, 435.	3.5	0
339	Frontispiece: Protein Metalation by Anticancer Metallo drugs: A Joint ESI MS and XRD Investigative Strategy. <i>Chemistry - A European Journal</i> , 2017, 23, .	3.3	0
340	Time course of antioxidant enzymes in the paraquat-resistant and tolerant <i>Heary fleabane</i> (<i>Conyza) Tj ETQq0 0 0 rgBT /Overlock 10 T <i>Journal of Biological and Chemical Sciences</i> , 2019, 13, 802.	0.2	0
341	Reactivity of CORM [RuII(CO)3Cl2{N-(N1-methylbenzimidazole)}] with aminoacids. Synthesis, and analytical and structural study for the new binuclear cis-[RuI(CO)2(N-MBI)(i ¹ / ₄ 2-O,O-BAL)]2 sawhorse complex at solid state and in solution. <i>Journal of Molecular Structure</i> , 2019, 1184, 479-486.	3.6	0